Ioduro (131i) De Sodio Ge Healthcare (Sodium Iodide (131i))

Sodium Iodide (131I) is absorbed by thyroid cells via the sodium‑iodide symporter. Once inside, the isotope emits beta particles that either generate images for diagnostic scans or provide therapeutic radiation that destroys overactive or malignant thyroid tissue while sparing most surrounding structures.

The dose of Ioduro (131i) De Sodio is individualized and determined by the prescribing physician based on the specific indication, patient weight, thyroid function, and treatment goals. No standard dosing can be provided without a medical assessment.

Radioactive iodine can cross the placenta and be secreted in breast milk, posing potential risks to the fetus or infant. Use during pregnancy or lactation is only considered when the benefit outweighs the risk and should be guided by a specialist.

To order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and import documentation.

Ioduro delivers Sodium Iodide (131I) in an oral solution, similar to other I‑131 preparations. Differences may lie in formulation purity, regulatory approvals, and supply chain reliability. Clinicians choose based on local licensing, dosing flexibility, and the supplier’s ability to meet quality and delivery standards.

Ioduro should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the solution from moisture, direct sunlight, and physical damage. Follow local regulations for handling radioactive materials and keep it out of reach of unauthorized personnel.

Ioduro is administered orally as a measured volume of solution. The patient drinks the dose under medical supervision, often after fasting or following specific preparation instructions to optimize thyroid uptake. Administration details are provided by the treating physician.

Serious risks include severe hypothyroidism, radiation thyroiditis, bone‑marrow suppression, allergic reactions, and, rarely, secondary malignancies. Patients should be monitored for signs of these events, and any sudden symptoms such as fever, unexplained bruising, or severe neck pain should prompt immediate medical evaluation.

Ioduro is contraindicated in pregnant or breastfeeding women unless absolutely necessary, individuals with known hypersensitivity to iodine or radioactive compounds, and patients with uncontrolled severe renal impairment where clearance cannot be assured. A thorough clinical assessment is required before use.